3 Biotech Stocks That Could Double In 2026

"The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the market, as growth in other sectors of the economy have led to valuations that now look more elevated than the biotech sector (in many cases). Traditionally one of the most volatile sectors in the market,"

"Focusing on rare neurodegenerative and lysosomal diseases, Denali Therapeutics (NASDAQ:DNLI) is a stock that many investors may rightly be cautious of, from the perspective of companies that have the potential to surge. That's due in part to the company's five-year return of -75%, signaling many in the market have moved away from this stock. Now, it's also true that a company that falls by such an amount over a five year period could snap back nicely,"

"I think Denali is among the more unique companies in the biologics space, using its patented transport vehicle platform to move biologics across the blood-brain barrier. The company's key programs could provide candidates for patients with Hunter Syndrome and other rare diseases, which could provide big upside of clinical trials perform as expected. Key earnings drivers for this year are milestone payments and collaboration revenue from Peters, if programs hit predefined clinical or regulatory milestones. For those who believe"

The biotech sector has warmed after a prolonged decade of stagnation, attracting investor interest as valuations in other sectors rose. Volatility remains high, but small- and mid-cap biotech names with imminent clinical or regulatory catalysts could deliver outsized returns through 2026. Selected companies have shown the ability to double quickly and present strong near-term catalysts. Denali Therapeutics focuses on rare neurodegenerative and lysosomal diseases, uses a patented transport vehicle to cross the blood-brain barrier, and carries risk after a five-year -75% return. Near-term upside hinges on clinical progress, milestone payments, and collaboration revenue tied to Peters.

Read at 24/7 Wall St.